Zolymbus is a drug owned by Thea Pharma Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 08, 2036. Details of Zolymbus's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10314780 | Drippable Opthalmic Bimatoprost Gel |
Jun, 2036
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Zolymbus's patents.
Latest Legal Activities on Zolymbus's Patents
Given below is the list of recent legal activities going on the following patents of Zolymbus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Nov, 2022 | US10314780 |
| Recordation of Patent Grant Mailed | 11 Jun, 2019 | US10314780 |
| Patent Issue Date Used in PTA Calculation | 11 Jun, 2019 | US10314780 |
| Email Notification | 23 May, 2019 | US10314780 |
| Issue Notification Mailed | 22 May, 2019 | US10314780 |
| Dispatch to FDC | 01 May, 2019 | US10314780 |
| Application Is Considered Ready for Issue | 29 Apr, 2019 | US10314780 |
| Issue Fee Payment Received | 24 Apr, 2019 | US10314780 |
| Issue Fee Payment Verified | 24 Apr, 2019 | US10314780 |
| Mail Notice of Allowance | 13 Feb, 2019 | US10314780 |
FDA has granted several exclusivities to Zolymbus. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Zolymbus, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Zolymbus.
Exclusivity Information
Zolymbus holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Zolymbus's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 09, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Zolymbus is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zolymbus's family patents as well as insights into
ongoing legal events
on those patents.
Zolymbus's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zolymbus's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 08, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zolymbus Generic API suppliers:
Bimatoprost is the generic name for the brand Zolymbus. 11 different companies have already filed for the generic of Zolymbus, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zolymbus's generic
Alternative Brands for Zolymbus
There are several other brand drugs in the same treatment category and using the same active ingredient (Bimatoprost) as Zolymbus. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Bimatoprost. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bimatoprost, Zolymbus's active ingredient. Check the complete list of approved generic manufacturers for Zolymbus
About Zolymbus
Zolymbus is a drug owned by Thea Pharma Inc. Zolymbus uses Bimatoprost as an active ingredient. Zolymbus was launched by Thea in 2025.
Approval Date:
Zolymbus was approved by FDA for market use on 09 September, 2025.
Active Ingredient:
Zolymbus uses Bimatoprost as the active ingredient. Check out other Drugs and Companies using Bimatoprost ingredient
Dosage:
Zolymbus is available in gel form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.01% | GEL | Prescription | OPHTHALMIC |